Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 2:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–109 of 109 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Philadelphia Chromosome Positive (Ph+) Phase Chronic Myelogenous Leukemia (CML) Clear all
Completed Phase 2 Interventional

Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia

NCT00110058
View directory record Official record
Conditions
Leukemia
Interventions
recombinant interferon alfa, therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate, imatinib mesylate, mycophenolate mofetil, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
Duarte, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 12, 2026, 2:28 AM EDT
Terminated Not applicable Interventional Results available

Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil

NCT00608517
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, cyclophosphamide, fludarabine phosphate, methylprednisolone, total-body irradiation
Biological · Drug · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Up to 50 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
4
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 12, 2026, 2:28 AM EDT
Terminated Phase 2 Interventional Results available

ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor

NCT04216563
View directory record Official record
Conditions
Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia
Interventions
Asciminib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 12, 2026, 2:28 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML

NCT07604233
View directory record Official record
Conditions
Myeloid Leukemia
Interventions
Fludarabine, Cytarabine, Idarubicin, Filgrastim, Venetoclax, Asciminib, Blinatumomab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 12, 2026, 2:28 AM EDT
Completed Phase 1 Interventional

Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders

NCT00114257
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
decitabine, romidepsin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 12, 2026, 2:28 AM EDT
Terminated Phase 1 Interventional

Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia

NCT02782403
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia (CML), Blast Phase Chronic Myelogenous Leukemia (CML), Chronic Phase Phase Chronic Myelogenous Leukemia (CML), Philadelphia Chromosome Positive (Ph+) Phase Chronic Myelogenous Leukemia (CML)
Interventions
Axitinib, Bosutinib, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 12, 2026, 2:28 AM EDT
Completed Phase 1Phase 2 Interventional

Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia

NCT00244829
View directory record Official record
Conditions
Leukemia
Interventions
imatinib mesylate, adjuvant therapy
Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Duarte, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 30, 2011 · Synced Oct 12, 2026, 2:28 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia

NCT00002674
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, cytarabine, etoposide, hydroxyurea, mitoxantrone hydrochloride, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
17 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2000
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 12, 2026, 2:28 AM EDT
Completed Phase 2 Interventional

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

NCT04188405
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions
Decitabine, Ponatinib, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 12, 2026, 2:28 AM EDT
Completed Phase 1 Interventional

Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia

NCT00816283
View directory record Official record
Conditions
Leukemia
Interventions
dasatinib, vorinostat, cytogenetic analysis, gene expression analysis, mutation analysis, reverse transcriptase-polymerase chain reaction, flow cytometry, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2012 · Synced Oct 12, 2026, 2:28 AM EDT
Completed Phase 2 Interventional Results available

Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI

NCT00363649
View directory record Official record
Conditions
Leukemia
Interventions
GM-K562 cell vaccine, Interferon alfa, Sargramostim
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Oct 12, 2026, 2:28 AM EDT
Completed Phase 1 Interventional

Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia

NCT00053144
View directory record Official record
Conditions
Leukemia
Interventions
cytarabine, irinotecan hydrochloride
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
15 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2011 · Synced Oct 12, 2026, 2:28 AM EDT
Completed Phase 2 Interventional

STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia

NCT00006052
View directory record Official record
Conditions
Leukemia
Interventions
imatinib mesylate
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 12, 2026, 2:28 AM EDT